Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LGND

Ligand Pharmaceuticals, Inc.

Last Close
May 06 • 04:00PM ET
72.83
Dollar change
-1.07
Percentage change
-1.45 		%
Held by: IJR VTI VB IWM VBR VXF IJS PJP IWN IBB
IndexRUT P/E25.11 EPS (ttm)2.90 Insider Own6.24% Shs Outstand17.56M Perf Week3.36%
Market Cap1.31B Forward P/E13.00 EPS next Y5.60 Insider Trans-0.18% Shs Float16.84M Perf Month-6.58%
Income52.15M PEG1.26 EPS next Q0.83 Inst Own91.74% Short Float4.91% Perf Quarter-2.53%
Sales131.31M P/S9.96 EPS this Y-27.09% Inst Trans-0.32% Short Ratio4.62 Perf Half Y40.57%
Book/sh39.92 P/B1.82 EPS next Y26.20% ROA6.94% Short Interest0.83M Perf Year-5.06%
Cash/sh9.48 P/C7.68 EPS next 5Y20.00% ROE8.29% 52W Range49.24 - 94.57 Perf YTD1.97%
Dividend Est.- P/FCF29.00 EPS past 5Y-13.18% ROI7.38% 52W High-22.99% Beta1.00
Dividend TTM- Quick Ratio12.72 Sales past 5Y-3.89% Gross Margin67.06% 52W Low47.91% ATR (14)2.40
Dividend Ex-DateJul 02, 2010 Current Ratio14.15 EPS Y/Y TTM253.69% Oper. Margin7.48% RSI (14)48.18 Volatility2.62% 3.20%
Employees58 Debt/Eq0.01 Sales Y/Y TTM-40.20% Profit Margin39.72% Recom1.20 Target Price116.80
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q199.40% Payout0.00% Rel Volume0.64 Prev Close73.90
Sales Surprise9.58% EPS Surprise108.87% Sales Q/Q-44.22% EarningsMay 07 AMC Avg Volume178.78K Price72.83
SMA20-2.67% SMA50-2.35% SMA2008.68% Trades Volume114,774 Change-1.45%
Date Action Analyst Rating Change Price Target Change
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Show Previous Ratings
Apr-23-24 08:31AM
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
(Business Wire)
Apr-17-24 09:55AM
Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
(Zacks)
Apr-08-24 08:15AM
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
(Business Wire)
Apr-05-24 06:00PM
Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts
(Zacks)
Apr-04-24 09:30AM
Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It?
(Zacks)
09:00AM Loading…
09:00AM
Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know
(Zacks)
Apr-03-24 09:00AM
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
(Business Wire)
Apr-01-24 06:15PM
Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note
(Zacks)
Mar-28-24 11:30AM
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
(Zacks)
Mar-26-24 06:15PM
Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know
(Zacks)
Mar-21-24 09:00AM
Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock
(Zacks)
Mar-20-24 06:00PM
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
(Zacks)
Mar-19-24 09:30AM
Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?
(Zacks)
Mar-14-24 06:00PM
Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
(Zacks)
Mar-07-24 09:00AM
Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now?
(Zacks)
04:01PM Loading…
Mar-05-24 04:01PM
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
(Business Wire)
Mar-04-24 08:00AM
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Feb-29-24 09:30AM
Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest?
(Zacks) -5.93%
Feb-28-24 07:34AM
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
(Zacks) -5.44%
Feb-27-24 07:00AM
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
(Business Wire) +19.86%
Feb-22-24 04:01PM
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa
(Business Wire)
Feb-16-24 08:00AM
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
(Business Wire)
Feb-13-24 04:01PM
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
(Business Wire) -6.13%
Feb-01-24 05:00PM
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jan-10-24 07:30PM
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
(GlobeNewswire)
Jan-05-24 04:30PM
U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
(Business Wire)
Dec-12-23 12:01PM
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
(Business Wire)
09:00AM
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
(GlobeNewswire)
09:00AM
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
(GlobeNewswire)
Dec-11-23 09:00AM
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
(GlobeNewswire)
04:02PM Loading…
Dec-06-23 04:02PM
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
(Business Wire)
Dec-01-23 08:20AM
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
(GlobeNewswire)
Nov-28-23 09:01AM
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
(GlobeNewswire)
Nov-09-23 04:47PM
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-08-23 04:01PM
Ligand Reports Third Quarter 2023 Financial Results
(Business Wire)
Nov-06-23 09:00AM
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
(GlobeNewswire)
Nov-01-23 08:00AM
Ligand Acquires Royalty on Sanofis TZIELD for $20 Million
(Business Wire)
Oct-25-23 04:01PM
Ligand To Report Third Quarter 2023 Financial Results On November 8
(Business Wire)
Oct-18-23 08:00AM
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026
(GlobeNewswire)
Oct-09-23 06:15PM
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
(Zacks)
Oct-03-23 06:00PM
Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know
(Zacks)
Oct-02-23 09:00AM
Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer
(GlobeNewswire)
09:00AM
Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms
(GlobeNewswire)
Sep-27-23 09:00AM
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
(Business Wire)
Sep-26-23 05:05PM
Ligand Appoints Martine Zimmermann to its Board of Directors
(Business Wire)
Sep-22-23 09:00AM
Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
(Business Wire)
Sep-21-23 09:20AM
Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
(Business Wire)
Sep-18-23 05:17PM
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
(Business Wire)
Sep-01-23 10:02PM
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
(Business Wire)
Aug-08-23 04:01PM
Ligand Reports Second Quarter 2023 Financial Results
(Business Wire)
Jul-27-23 01:30PM
Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
(Business Wire)
Jul-25-23 04:30PM
Ligand To Report Second Quarter 2023 Financial Results On August 8
(Business Wire)
Jul-17-23 08:59AM
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
(Business Wire)
08:45AM
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
(GlobeNewswire)
Jun-29-23 09:00AM
Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
(GlobeNewswire)
Jun-21-23 08:00PM
LGND: Lowering target price to $81.00
(Argus Research)
Jun-09-23 09:40AM
Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?
(Zacks)
Jun-06-23 11:40AM
LGND or ILMN: Which Is the Better Value Stock Right Now?
(Zacks)
11:10AM
UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health
(Zacks)
Jun-05-23 11:49AM
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
(Zacks) -5.72%
09:01AM
Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
(GlobeNewswire)
Jun-02-23 12:39PM
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
(Zacks) +5.77%
12:35PM
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
(Zacks)
Jun-01-23 11:29AM
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
(Zacks)
May-30-23 07:01PM
3 Stocks That Smart Investors Should Be Flocking to Now
(InvestorPlace)
May-25-23 05:00PM
Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
(GlobeNewswire)
May-24-23 09:55AM
Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet
(Zacks)
09:40AM
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
(Zacks)
May-17-23 01:59PM
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
(Zacks)
08:07AM
Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen
(Zacks)
May-16-23 09:56AM
Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far
(Zacks)
07:30AM
Ligands Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
(Business Wire)
07:00AM
Load Up on These 5 Exceptional Relative Price Strength Stocks
(Zacks)
May-12-23 12:08PM
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
(Zacks)
11:34AM
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
(Zacks)
May-11-23 12:25PM
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
(Zacks)
May-08-23 12:32PM
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
(Zacks)
09:55AM
Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade
(Zacks)
May-06-23 10:13AM
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
(Simply Wall St.)
May-05-23 10:00AM
Best Momentum Stocks to Buy for May 5th
(Zacks)
May-04-23 05:45PM
Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates
(Zacks)
04:01PM
Ligand Reports First Quarter 2023 Financial Results
(Business Wire)
06:26AM
10 Best Small-Cap Growth Stocks to Buy Now
(Insider Monkey)
May-02-23 08:30PM
2 Medical Stocks to Buy Before Earnings
(Zacks)
12:06PM
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
(Zacks)
11:40AM
LGND vs. REGN: Which Stock Is the Better Value Option?
(Zacks)
Apr-28-23 02:04PM
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
(Zacks)
Apr-27-23 09:04AM
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
(Zacks)
Apr-26-23 08:00PM
LGND: Lowering target price to $81.00
(Argus Research)
Apr-24-23 04:01PM
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
(Business Wire)
Apr-20-23 09:55AM
Does Ligand (LGND) Have the Potential to Rally 41.24% as Wall Street Analysts Expect?
(Zacks)
Apr-19-23 08:30AM
Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today
(Zacks)
Apr-18-23 12:56PM
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
(Zacks)
Apr-17-23 01:13PM
Bristol Myers (BMY), TSVT Application for Abecma Accepted
(Zacks)
09:40AM
Is Hologic (HOLX) Outperforming Other Medical Stocks This Year?
(Zacks)
Apr-14-23 01:48PM
Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer
(Zacks)
Apr-13-23 06:28AM
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 41%?
(Simply Wall St.)
Apr-07-23 06:40PM
Tillys, American Public Education Stock See Action From Activist Investors
(Barrons.com)
Apr-06-23 10:23AM
Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio
(Zacks)
Apr-04-23 12:02PM
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
(Zacks)
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aryeh JasonDirectorApr 30 '24Option Exercise52.302,406125,83476,828May 02 06:07 PM
KOZARICH JOHN WDirectorApr 24 '24Option Exercise39.352,893113,84042,523Apr 26 06:35 PM
Davis Todd CChief Executive OfficerMar 25 '24Option Exercise57.3916,015919,147120,160Mar 27 05:47 PM
Aryeh JasonDirectorMar 05 '24Option Exercise39.352,893113,84074,422Mar 06 05:28 PM
Sabba Stephen LDirectorMar 05 '24Option Exercise0.002,893030,819Mar 07 01:27 PM
Sabba Stephen LDirectorMar 05 '24Sale74.301,893140,65028,926Mar 07 01:27 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Option Exercise56.621,26471,56429,895Feb 29 06:50 PM
Espinoza OctavioChief Financial OfficerFeb 28 '24Sale88.4614012,38429,755Feb 29 06:50 PM
Davis Todd CCHIEF EXECUTIVE OFFICERSep 22 '23Buy59.384,000237,52973,090Sep 25 04:44 PM
KOZARICH JOHN WDirectorMay 16 '23Sale77.204,444343,08138,488May 18 05:18 PM
Sabba Stephen LDirectorMay 10 '23Option Exercise0.006,408032,192May 12 03:43 PM
Sabba Stephen LDirectorMay 10 '23Sale77.136,408494,22525,784May 12 03:43 PM
KOZARICH JOHN WDirectorMay 08 '23Option Exercise18.826,408120,59948,621May 10 07:15 PM
KOZARICH JOHN WDirectorMay 08 '23Sale76.566,408490,62842,213May 10 07:15 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

OBIO

Orchestra BioMed Holdings Inc

Last Close
May 06 • 04:00PM ET
5.24
Dollar change
+0.14
Percentage change
2.75 		%
OBIO Orchestra BioMed Holdings Inc daily Stock Chart
Held by: VTI VXF IWM IWO SCHA VTWO IWC SCHB VTWG RYLD
IndexRUT P/E- EPS (ttm)-1.48 Insider Own37.91% Shs Outstand35.78M Perf Week19.36%
Market Cap187.54M Forward P/E- EPS next Y-1.78 Insider Trans0.00% Shs Float22.22M Perf Month7.16%
Income-49.12M PEG- EPS next Q-0.40 Inst Own36.42% Short Float3.75% Perf Quarter-25.36%
Sales2.76M P/S67.95 EPS this Y-8.41% Inst Trans-31.91% Short Ratio18.40 Perf Half Y-0.38%
Book/sh1.90 P/B2.76 EPS next Y-10.87% ROA-60.16% Short Interest0.83M Perf Year-64.06%
Cash/sh2.45 P/C2.14 EPS next 5Y- ROE-76.29% 52W Range4.22 - 20.19 Perf YTD-42.61%
Dividend Est.- P/FCF- EPS past 5Y- ROI-71.10% 52W High-74.05% Beta0.23
Dividend TTM- Quick Ratio7.94 Sales past 5Y-7.29% Gross Margin74.11% 52W Low24.17% ATR (14)0.38
Dividend Ex-Date- Current Ratio7.95 EPS Y/Y TTM-697.79% Oper. Margin-1866.16% RSI (14)56.83 Volatility11.46% 6.86%
Employees56 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin-1779.71% Recom1.00 Target Price16.33
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q-358.18% Payout- Rel Volume0.74 Prev Close5.10
Sales Surprise-73.66% EPS Surprise7.04% Sales Q/Q- EarningsMar 27 AMC Avg Volume45.29K Price5.24
SMA2011.13% SMA50-1.41% SMA200-19.52% Trades Volume33,575 Change2.75%
Date Action Analyst Rating Change Price Target Change
Jan-19-24Initiated Jefferies Buy $14
Feb-24-23Initiated Piper Sandler Overweight $15
Feb-07-23Initiated Chardan Capital Markets Buy $20
Apr-30-24 08:30AM
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
(GlobeNewswire)
08:00AM
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
(GlobeNewswire)
Mar-27-24 04:17PM
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
(GlobeNewswire)
Mar-26-24 08:00AM
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
(GlobeNewswire) +5.20%
Mar-13-24 08:00AM
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
(GlobeNewswire)
08:00AM Loading…
Mar-07-24 08:00AM
Orchestra BioMed to Participate in Upcoming Investor Conferences
(GlobeNewswire) -6.62%
Mar-06-24 08:37AM
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
(GlobeNewswire)
Feb-26-24 08:00AM
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
(GlobeNewswire)
Feb-16-24 09:13AM
Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season
(Zacks) -8.45%
Jan-08-24 07:30AM
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
(GlobeNewswire) +9.38%
Nov-13-23 04:21PM
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) +14.61%
Nov-09-23 04:42PM
Orchestra BioMed to Present at Upcoming Investor Conferences
(GlobeNewswire)
Oct-30-23 03:52PM
Billionaire Marc Lasrys Top 10 Stock Picks
(Insider Monkey)
Sep-22-23 11:27AM
Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline
(American City Business Journals)
Sep-19-23 02:37PM
Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach
(TheStreet.com) +27.61%
07:30AM Loading…
07:30AM
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients
(GlobeNewswire)
Sep-06-23 05:00PM
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors
(GlobeNewswire)
Aug-10-23 04:34PM
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) +7.05%
Aug-08-23 08:30AM
Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis
(GlobeNewswire)
Jul-27-23 09:47AM
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28%
(Simply Wall St.) -14.00%
Jun-28-23 02:16PM
Why Shares of Orchestra BioMed Holdings Jumped Wednesday
(Motley Fool) +24.85%
Jun-26-23 08:00AM
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
(GlobeNewswire) -9.81%
Jun-07-23 08:30AM
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
(GlobeNewswire) -6.42%
Jun-01-23 08:00AM
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) +8.93%
May-12-23 09:15AM
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Apr-11-23 05:39AM
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
(Motley Fool) +10.12%
Mar-27-23 06:05AM
Orchestra BioMed Holdings Full Year 2022 Earnings: US$14.60 loss per share (vs US$10.90 loss in FY 2021)
(Simply Wall St.)
Mar-24-23 03:52PM
Why Shares of Orchestra BioMed Jumped This Week
(Motley Fool)
Mar-07-23 08:00AM
Orchestra BioMed to Present at Upcoming Investor Conferences
(GlobeNewswire) -6.77%
Feb-24-23 08:00AM
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT and Virtue® SAB at CRT 2023
(GlobeNewswire)
08:00AM Loading…
Feb-07-23 08:00AM
Orchestra BioMed Strengthens Senior Leadership Team
(GlobeNewswire)
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSE ERIC A MDDirectorMay 17 '23Option Exercise1.082,3252,5112,325May 19 06:15 PM
Fain Eric SDirectorMay 10 '23Option Exercise1.082,9063,13829,767May 12 04:59 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.